EAM
COCH icon

Exos Asset Management’s Envoy Medical COCH Stock Holding History

Exos Asset Management’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-39,423
Closed -$384K – 323
2021
Q4 		$384K Hold
39,423
– – 0.2% 143
2021
Q3 		$383K Buy
+39,423
New +$382K 0.2% 148

Other funds holding COCH

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Exos Asset Management's COCH Position: Q1 2022 in Review

Exos Asset Management sold out of Envoy Medical (COCH) in Q1 2022, closing a stake of 39,423 shares — an estimated $384K sold.

Exos Asset Management first reported a position in COCH in Q3 2021 and held it in 2 quarters. The position peaked at $384K in Q4 2021. 84 funds tracked by Wall St. Rank hold COCH as of Q1 2022.

  • Exos Asset Management reported no remaining Envoy Medical position as of Q1 2022 after selling out during the quarter.
  • Exos Asset Management sold 39,423 Envoy Medical shares in Q1 2022, an estimated $384K.
  • Exos Asset Management first reported a position in Envoy Medical in Q3 2021 and held it in 2 quarters.
  • Exos Asset Management's Envoy Medical position peaked at $384K in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2022.

Based on Exos Asset Management's 13F filing for Q1 2022, filed 13 Apr 2022.